<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385606</url>
  </required_header>
  <id_info>
    <org_study_id>GECO</org_study_id>
    <nct_id>NCT00385606</nct_id>
  </id_info>
  <brief_title>GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polychemotherapy With Cisplatin and Gemcitabine and the Fixed Dose Rate Infusion of Gemcitabine in Association With Cisplatin in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and efficacy of the addition of
      rofecoxib to first-line chemotherapy, and to evaluate the efficacy of prolonged continuous
      infusion of gemcitabine in combination with cisplatin in the treatment of patients affected
      by advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary end-points of the GECO study

        -  To evaluate the tolerability of three innovative schedules of treatment for advanced
           NSCLC

        -  To evaluate the efficacy of the addition of rofecoxib to first-line chemotherapy in the
           treatment of patients affected by advanced NSCLC

        -  To evaluate the efficacy of prolonged continuous infusion (p.c.i.) of gemcitabine, with
           the fixed infusion rate of 10 mg/sqm/minute) versus the standard administration in 30
           minutes, in combination with cisplatin, in the treatment of patients affected by
           advanced NSCLC

      Four treatment arms are planned.

        -  ARM A standard treatment : cisplatin + gemcitabine

        -  ARM B cisplatin + gemcitabine + rofecoxib

        -  ARM C cisplatin + p.c.i. gemcitabine (10 mg/sqm/minute)

        -  ARM D cisplatin + p.c.i gemcitabine (10 mg/sqm/minute) + rofecoxib

      The phase II part of the study for experimental arms B, C and D will be conducted to evaluate
      tolerability in the three treatment arms.

      The phase III study for efficacy has been designed according to a factorial 2x2 model with
      the planned comparison of

        -  The efficacy of rofecoxib: A + C (arms without rofecoxib) vs B+D (arms with rofecoxib)

        -  The efficacy of p.c.i. gemcitabine: A + B (arms with standard infusion of gemcitabine)
           vs C+ D (arms with p.c.i gemcitabine)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the tolerability of three experimental treatment schedules</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of the addition of rofecoxib to first-line chemotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of prolonged continuous infusion (p.c.i.) of gemcitabine vs standard infusion, in combination with cisplatin</measure>
  </primary_outcome>
  <enrollment>400</enrollment>
  <condition>Advanced Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prolonged continuous infusion gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rofecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic diagnosis of non-small cell lung cancer

          -  Disease stage IIIB or IV

          -  Age less than 70 years

          -  ECOG performance status 2 or less

          -  Patients with cerebral metastases are permitted if they are asymptomatic and do not
             require radiation therapy concomitant with chemotherapy

          -  Negative history of allergy to non-steroidal anti-inflammatory and/or sulphonamide
             drugs

          -  Patients previously treated with radiation therapy are permitted if at least 4 weeks
             have passed since last therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy

          -  Previous or concomitant malignant neoplasm (excluding adequately treated baso or
             spinocellular skin carcinoma or carcinoma in situ of the cervix)

          -  Neutrophil &lt; 2000/mm3, platelets &lt; 100,000/mm3, haemoglobin &lt; 10 g/dl

          -  Creatinine &gt; 1.25 x the upper normal limits

          -  GOT and/or GPT and/or Bilirubin &gt; 1.25 the upper normal limits in absence of hepatic
             metastases

          -  GOT and/or GPT and/or Bilirubin &gt; 2.5 the upper normal limits in presence of hepatic
             metastases

          -  Any concomitant pathology that would, in the investigator's opinion, contraindicate
             the use of the drugs in this study

          -  Inability to comply with follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Giuseppe Moscati Hospital, Avellino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <zip>83024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Miulli, Divisione Medicina Interna Sezione Oncologica</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Bari, Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico di Bari, U.O. di Oncologia Medica e Sperimentale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario, Oncologia Medica II</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Cardarelli</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mariano Santo, U.O. di Oncologia Medica</name>
      <address>
        <city>Cosenza</city>
        <state>CS</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto di Frosinone</name>
      <address>
        <city>Frosinone</city>
        <state>FR</state>
        <zip>03031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I, Day Hospital Oncoematologico</name>
      <address>
        <city>Nocera Inferiore</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica, U.S.L.L. 13</name>
      <address>
        <city>.Noale</city>
        <state>VE</state>
        <zip>30033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale L. Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second University of Naples</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Corona</name>
      <address>
        <city>Pietre Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena, Divisione di Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Gatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo - Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Busto Arsizio</name>
      <address>
        <city>Saronno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007 Jun;8(6):500-12.</citation>
    <PMID>17513173</PMID>
  </results_reference>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>August 22, 2007</last_update_submitted>
  <last_update_submitted_qc>August 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2007</last_update_posted>
  <keyword>prolonged continuous infusion</keyword>
  <keyword>Cox-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Rofecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

